RTX vs SRPT · P/E 36, rev $88.60B vs rev $1.90B
RTX Corporation (RTX) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the RTX and SRPT stock pages for the full models.
Not investment advice.